06.06.2026
eye drop — CA news
K.C. Pharmaceuticals has recalled over 3 million bottles of eye drops due to sterility concerns, affecting major retailers and consumers nationwide.

In a significant health alert, K.C. Pharmaceuticals has recalled over 3.1 million bottles of lubricating eye drops due to serious sterility issues. This recall, initiated on March 3, 2026, includes eight products such as Dry Eye Relief Eye Drops and Artificial Tears Sterile Lubricant Eye Drops.

The affected products were sold at major retailers like Walgreens, CVS, and Kroger. Consumers should check their cabinets—expiration dates for the recalled items range from April 30, 2026, to October 31, 2026.

Fortunately, as of early April 2026, no infections linked to these specific eye drops have been reported. However, this situation echoes a troubling pattern; in 2023 alone, 81 people developed severe eye infections from contaminated eye drops, leading to multiple recalls and heightened scrutiny of manufacturing practices.

The FDA has previously identified sterility issues at K.C. Pharmaceuticals and has issued a warning letter regarding their manufacturing practices. The agency had inspected over-the-counter eye drop manufacturers only a handful of times before the alarming outbreak in 2023.

That year was particularly grim: four people lost their eyesight entirely after using contaminated products, while four others died from related infections. The FDA identified two brands—EzriCare Artificial Tears and Delsem Pharma’s Artificial Tears—as culprits in that outbreak.

As concerns grow about the safety of over-the-counter eye drops, experts are stressing the importance of using sterile products. A clinical pharmacologist warned that “using nonsterile eye drops that harbor bacteria and fungus can cause eye infections,” which can escalate quickly because the immune system struggles to reach the eyeball effectively.

If you find your product has been recalled, stop using it immediately and return it to the store for a refund. Many consumers remain unaware of these risks; education is crucial.

With limited FDA personnel focusing inspections on higher-risk products, vigilance from both manufacturers and consumers is essential to prevent future outbreaks. As this situation develops, many will be watching closely for updates on safety protocols in the industry.